Earnings Summary

REGENXBIO

06/08/2026 13:53

REGENXBIO Inc. RGNX.OQ reported quarterly adjusted earnings of 43 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.38.  The mean expectation of eleven analysts for the quarter was for earnings of 6 cents per share. Wall Street expected results to range from $-1.23 to 73 cents per share.
Revenue fell 80.4% to $4.18 million from a year ago; analysts expected $117.13 million. 
REGENXBIO Inc. shares had fallen by 12.4% this quarter and lost 27.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 79% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for REGENXBIO Inc. is $22.50, about 53.3% above its last closing price of $10.50
This summary was machine generated from LSEG data August 6 at 12:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.06
0.43
Beat
Mar. 31 2026 
-1.34
-1.72
Missed
Dec. 31 2025 
-0.96
-1.30
Missed
Sep. 30 2025 
-1.31
-1.20
Beat